Is NCT06799026 recruiting in Boston, MA?

Yes, NCT06799026 is currently recruiting participants at its Boston, MA location. This multiple myeloma clinical trial is actively enrolling qualified participants.

How do I join the multiple myeloma clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Multiple Myeloma Clinical Trial in Boston, MA

About This Multiple Myeloma Study in Boston

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in this study are: * DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells) * Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor) * Elranatamab (a type of T-cell engager antibody)

Sponsor: David Avigan

Who Can Participate

Inclusion Criteria

for Tumor Collection:

Participants must have an established diagnosis of multiple myeloma

Participant must have multiple myeloma and have relapsed following or are refractory to proteasome inhibitors, IMiDs and anti-CD38 mAb therapy

Participants must have at least 3 prior lines of therapy

Participants must be ≥18 years of age

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Participants must have \> 20% plasma cells in the bone marrow core or aspirate differential \<30 days prior to enrollment.

ANC \> 1K/uL; Platelets \> 50 K/uL without transfusional support

Participants must have adequate organ function as defined below:

Total bilirubin ≤1.5 x institutional upper limit of normal

AST ≤ 3 x institutional upper limit of normal

ALT ≤ 3 x institutional upper limit of normal

Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal

The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment.

Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

for Tumor Collection:

Patients who are receiving any other investigational agents.

Patients with purely non-secretory MM \[absence of a monoclonal protein (M protein) in serum as measured by electrophoresis and immunofixation and the absence of Bence- Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques and the absence of involved serum free light chain \>100 mg/L\]. Patients with light chain MM detected in the serum by free light chain assay are eligible.

Patients with Plasma Cell Leukemia

Because of compromised cellular immunity, patients who have a known human immunodeficiency virus (HIV), active hepatitis C virus (HCV) or active hepatitis B virus (HBV).

Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant.

Active and clinically significant autoimmune or inflammatory disorder requiring active treatment

Individuals with a history of a different malignancy are ineligible except for the following circumstances. Note: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: non- invasive cancer (such as, any in situ cancers) and basal cell or squamous cell carcinoma of the skin.

Female patients who are pregnant (positive β-HCG) or breastfeeding

Prior organ transplant requiring immunosuppressive therapy.

Patients who previously received PD-1 antibody and have experienced toxicities resulting in treatment discontinuation.

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy. Eligibility Criteria Prior to Vaccination with DC/MM fusions

Resolution of all elranatamab related ≥ grade 3 or higher toxicities to grade 1 or baseline. Isolated laboratory abnormalities that are not considered to be clinically significant are not exclusionary.

Successful production of at least 2 vaccines with a minimum of 1 x 106 fusion cells per vaccine

Absence of disease progression following 2 cycles of elranatamab therapy

ECOG performance status ≤ 2 Participants must have adequate organ function as defined below:

Total bilirubin ≤ 1.5 x institutional upper limit of normal

AST ≤ 3 x institutional upper limit of normal

ALT ≤ 3 x institutional upper limit of normal

ANC \> 1K/uL; Platelets \> 50 K/uL without transfusional support

Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06799026) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Myeloma Treatment Options in Boston, MA

If you're searching for multiple myeloma treatment options in Boston, MA, this clinical trial (NCT06799026) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple myeloma clinical trials near you to find additional studies recruiting in your area.

Multiple Myeloma Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process